Jordan Lachnish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jordan Lachnish has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Tomer Bashi
Department of Urology Tel Aviv Sourasky Medical Center Tel Aviv‐Yafo Israel
3 shared publications Dana Ben-Ami Shor
2 shared publications- Jeffrey Yao
Stanford University
2 shared publications - Miri Blank
Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Ramat Gan, Israel
2 shared publications - Yehuda Shoenfeld
Medical School, Reichman University, Herzliya 4610101, Israel
2 shared publications - Alexander Volkov
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel
1 shared publication
Latest Publications
- 5 December 2025
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 51 (4) , 428.e1-428.e8
Single-Stage Versus Staged Fasciectomy for Severe PIPJ Contractures in Dupuytren Disease: A Retrospective Comparative Study
- 5 December 2025
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 51 (4) , 428.e1-428.e8
Single-Stage Versus Staged Fasciectomy for Severe PIPJ Contractures in Dupuytren Disease: A Retrospective Comparative Study
- 1 February 2024
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 30 (3-4) , 107-114
Scaffold-Free Bone Marrow-Derived Mesenchymal Stem Cell Sheets Enhance Bone Formation in a Weight-Bearing Rat Critical Bone Defect Model
Researchers have been exploring alternative methods for bone tissue engineering, as current management of large bone defects may be a significant challenge for both patient and surgeon with conventional surgical treatments leading to high complication and revision rates. Recent studies have shown mesenchymal stem cell sheets may enhance bone regeneration in different animal models. We investigated the efficacy of implanted scaffold-free bone marrow-derived mesenchymal stem cell (BMSC) sheets on bone regeneration of a critical bone defect in a weight-bearing rat model. BMSCs were isolated from the femora of male Sprague-Dawley rats aged 5-6 weeks and cell sheets were produced on temperature-responsive culture dishes. Nine male Sprague-Dawley rats aged 6-8 weeks were utilized. A bilateral femoral critical bone defect was created with a bridge plate serving as internal fixation. One side was randomly selected and BMSC sheets were implanted into the bone defect (BMSC group), with the contralateral side receiving no treatment (control). Rats were anesthetized and radiographs were performed at 2-week intervals. At the 8-week timepoint, rats were euthanized, femurs harvested and micro-CT and histologic analysis was performed. We found a statistically significant increase in new bone formation and bone volume fraction compared to the control. Histomorphometry analysis revealed a larger percent of newly formed bone and a higher total histologic score. Our results suggest scaffold-free BMSC sheets may be used in the management of large weight-bearing bone defects to complement a different surgical technique or as a standalone approach followed by internal fixation. However further research is still needed.
- 1 February 2024
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 30 (3-4) , 107-114
Scaffold-Free Bone Marrow-Derived Mesenchymal Stem Cell Sheets Enhance Bone Formation in a Weight-Bearing Rat Critical Bone Defect Model
Researchers have been exploring alternative methods for bone tissue engineering, as current management of large bone defects may be a significant challenge for both patient and surgeon with conventional surgical treatments leading to high complication and revision rates. Recent studies have shown mesenchymal stem cell sheets may enhance bone regeneration in different animal models. We investigated the efficacy of implanted scaffold-free bone marrow-derived mesenchymal stem cell (BMSC) sheets on bone regeneration of a critical bone defect in a weight-bearing rat model. BMSCs were isolated from the femora of male Sprague-Dawley rats aged 5-6 weeks and cell sheets were produced on temperature-responsive culture dishes. Nine male Sprague-Dawley rats aged 6-8 weeks were utilized. A bilateral femoral critical bone defect was created with a bridge plate serving as internal fixation. One side was randomly selected and BMSC sheets were implanted into the bone defect (BMSC group), with the contralateral side receiving no treatment (control). Rats were anesthetized and radiographs were performed at 2-week intervals. At the 8-week timepoint, rats were euthanized, femurs harvested and micro-CT and histologic analysis was performed. We found a statistically significant increase in new bone formation and bone volume fraction compared to the control. Histomorphometry analysis revealed a larger percent of newly formed bone and a higher total histologic score. Our results suggest scaffold-free BMSC sheets may be used in the management of large weight-bearing bone defects to complement a different surgical technique or as a standalone approach followed by internal fixation. However further research is still needed.
- 1 May 2022
- Vol. 24 (5) , 293-298
Early Postoperative Complications and Ambulation in Patients Treated for Hip Fractures, the Unexpected Positive Influence of the COVID-19 Pandemic: A Comparison Study
Background: The influence of the coronavirus disease 2019 (COVID-19) pandemic caused countries worldwide to implement lockdowns. Elective surgeries were temporarily suspended, with surgeries being performed only for emergent/urgent medical conditions such as hip fractures where early surgical intervention has shown decreased rates of morbidity/mortality. Objectives: To assess the indirect influence of the COVID-19 pandemic and associated lockdown on hip fracture patients, considering factors such as time to surgery, early postoperative complications, and ambulation status. Methods: A comparative retrospective study was conducted on consecutive patients presenting to our emergency department (ED) with hip fractures that were treated surgically (N=29) during a 1-month period during the government lockdown due to the COVID-19 pandemic. The treatments were compared to consecutive patients who presented with hip fractures and were treated surgically (N=44) during the same timeframe in the previous year (control). Comparisons were made using t-test, ANOVA test, Fishers exact test, and chi-square test. Results: The COVID-19 group was operated on sooner (2034 vs. 34.87 hours), had fewer early postoperative complications (10.3% vs. 31.8%), had better ambulatory status at discharge, and experienced a shorter hospital stay (5.93 vs. 8.13 days) with more patients being discharged home (72.4% vs. 22.7%). Conclusions: Patients presenting with hip fractures to our ED during the COVID-19 pandemic lockdown indirectly benefited from this situation by undergoing earlier surgical treatment, thus experiencing fewer early postoperative complications, faster ambulation, and sooner discharge.
- 1 May 2022
- Vol. 24 (5) , 293-298
Early Postoperative Complications and Ambulation in Patients Treated for Hip Fractures, the Unexpected Positive Influence of the COVID-19 Pandemic: A Comparison Study
Background: The influence of the coronavirus disease 2019 (COVID-19) pandemic caused countries worldwide to implement lockdowns. Elective surgeries were temporarily suspended, with surgeries being performed only for emergent/urgent medical conditions such as hip fractures where early surgical intervention has shown decreased rates of morbidity/mortality. Objectives: To assess the indirect influence of the COVID-19 pandemic and associated lockdown on hip fracture patients, considering factors such as time to surgery, early postoperative complications, and ambulation status. Methods: A comparative retrospective study was conducted on consecutive patients presenting to our emergency department (ED) with hip fractures that were treated surgically (N=29) during a 1-month period during the government lockdown due to the COVID-19 pandemic. The treatments were compared to consecutive patients who presented with hip fractures and were treated surgically (N=44) during the same timeframe in the previous year (control). Comparisons were made using t-test, ANOVA test, Fishers exact test, and chi-square test. Results: The COVID-19 group was operated on sooner (2034 vs. 34.87 hours), had fewer early postoperative complications (10.3% vs. 31.8%), had better ambulatory status at discharge, and experienced a shorter hospital stay (5.93 vs. 8.13 days) with more patients being discharged home (72.4% vs. 22.7%). Conclusions: Patients presenting with hip fractures to our ED during the COVID-19 pandemic lockdown indirectly benefited from this situation by undergoing earlier surgical treatment, thus experiencing fewer early postoperative complications, faster ambulation, and sooner discharge.
- Open Access
- 26 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (1) , 65
Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine
Helminths or their products can immunomodulate the host immune system, and this phenomenon may be applied as the basis of new anti-inflammatory treatments. Previously, we have shown the efficacy of tuftsin–phosphorylcholine (TPC), based on a helminth product, in four animal models of autoimmune diseases: arthritis, colitis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis. We demonstrated that TPC reduced inflammatory process ex vivo in peripheral blood lymphocytes (PBLs) and in biopsies from giant-cell arteritis. In the present study, we assessed the therapeutic potential of TPC treatment on a chronic colitis murine model. C57BL/6 mice with chronic colitis were treated with TPC after the third cycle of 2% dextran sodium sulfate (DSS). Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1β, IL17, IL-6, TNFα), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR). This study demonstrated the potential immunomodulatory effects of oral administration of TPC in a chronic colitis murine model. Further clinical trials are needed in order to evaluate this novel approach for the treatment of patients with inflammatory bowel disease.
- 26 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (1) , 65
Open AccessImmunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine
Helminths or their products can immunomodulate the host immune system, and this phenomenon may be applied as the basis of new anti-inflammatory treatments. Previously, we have shown the efficacy of tuftsin–phosphorylcholine (TPC), based on a helminth product, in four animal models of autoimmune diseases: arthritis, colitis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis. We demonstrated that TPC reduced inflammatory process ex vivo in peripheral blood lymphocytes (PBLs) and in biopsies from giant-cell arteritis. In the present study, we assessed the therapeutic potential of TPC treatment on a chronic colitis murine model. C57BL/6 mice with chronic colitis were treated with TPC after the third cycle of 2% dextran sodium sulfate (DSS). Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1β, IL17, IL-6, TNFα), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR). This study demonstrated the potential immunomodulatory effects of oral administration of TPC in a chronic colitis murine model. Further clinical trials are needed in order to evaluate this novel approach for the treatment of patients with inflammatory bowel disease.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S573-S574
Helminthes Derivative for Treating Acute and Chronic Colitis in Mice Models
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S573-S574
Helminthes Derivative for Treating Acute and Chronic Colitis in Mice Models